Literature DB >> 21593147

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

Marit J van Gils1, Evelien M Bunnik, Brigitte D Boeser-Nunnink, Judith A Burger, Marijke Terlouw-Klein, Naomi Verwer, Hanneke Schuitemaker.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) has the ability to adapt to the host environment by escaping from host immune responses. We previously observed that escape from humoral immunity, both at the individual and at a population level, coincided with longer variable loops and an increased number of potential N-linked glycosylation sites (PNGS) in the viral envelope glycoprotein (Env) and, in particular, in variable regions 1 and 2 (V1V2). Here, we provide several lines of evidence for the role of V1V2 in the resistance of HIV-1 to neutralizing antibodies. First, we determined that the increasing neutralization resistance of a reference panel of tier-categorized neutralization-sensitive and -resistant HIV-1 variants coincided with a longer V1V2 loop containing more PNGS. Second, an exchange of the different variable regions of Env from a neutralization-sensitive HIV-1 variant into a neutralization-resistant escape variant from the same individual revealed that the V1V2 loop is a strong determinant for sensitivity to autologous-serum neutralization. Third, exchange of the V1V2 loop of neutralization-sensitive HIV-1 variants from historical seroconverters with the V1V2 loop of neutralization-resistant HIV-1 variants from contemporary seroconverters decreased the neutralization sensitivity to CD4-binding site-directed antibodies. Overall, we demonstrate that an increase in the length of the V1V2 loop and/or the number of PNGS in that same region of the HIV-1 envelope glycoprotein is directly involved in the protection of HIV-1 against HIV-specific neutralizing antibodies, possibly by shielding underlying epitopes in the envelope glycoprotein from antibody recognition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593147      PMCID: PMC3126602          DOI: 10.1128/JVI.00268-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Authors:  Zelda Euler; Evelien M Bunnik; Judith A Burger; Brigitte D M Boeser-Nunnink; Marlous L Grijsen; Jan M Prins; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

4.  Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag.

Authors:  M Tersmette; I N Winkel; M Groenink; R A Gruters; R P Spence; E Saman; G Van Der Groen; F Miedema; J G Huisman
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

5.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

Authors:  A B van't Wout; N A Kootstra; G A Mulder-Kampinga; N Albrecht-van Lent; H J Scherpbier; J Veenstra; K Boer; R A Coutinho; F Miedema; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

8.  Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.

Authors:  Tim Beaumont; Esther Quakkelaar; Ad van Nuenen; Ralph Pantophlet; Hanneke Schuitemaker
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

View more
  55 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

2.  Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Authors:  Zelda Euler; Tom L G M van den Kerkhof; Marit J van Gils; Judith A Burger; Diana Edo-Matas; Pham Phung; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

3.  Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus.

Authors:  Jennifer D Watkins; Juan Diaz-Rodriguez; Nagadenahalli B Siddappa; Davide Corti; Ruth M Ruprecht
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

4.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

5.  Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.

Authors:  Anjali Joshi; Raphael T C Lee; Jonathan Mohl; Melina Sedano; Wei Xin Khong; Oon Tek Ng; Sebastian Maurer-Stroh; Himanshu Garg
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

6.  Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.

Authors:  Axel Mann; Nikolas Friedrich; Anders Krarup; Jacqueline Weber; Emanuel Stiegeler; Birgit Dreier; Pavel Pugach; Melissa Robbiani; Tina Riedel; Kerstin Moehle; John A Robinson; Peter Rusert; Andreas Plückthun; Alexandra Trkola
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

7.  Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.

Authors:  Gustavo H Kijak; Sodsai Tovanabutra; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirapa Eamsila; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Chawetsan Namwat; Nakorn Premsri; Michael Benenson; Patricia Morgan; Meera Bose; Eric Sanders-Buell; Robert Paris; Merlin L Robb; Deborah L Birx; Mark S De Souza; Francine E McCutchan; Nelson L Michael; Jerome H Kim
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

8.  Noninvasive follow-up of simian immunodeficiency virus infection in wild-living nonhabituated western lowland gorillas in Cameroon.

Authors:  Lucie Etienne; Sabrina Locatelli; Ahidjo Ayouba; Amandine Esteban; Christelle Butel; Florian Liegeois; Avelin Aghokeng; Eric Delaporte; Eitel Mpoudi Ngole; Martine Peeters
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

9.  Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.

Authors:  Marit J van Gils; Diana Edo-Matas; Emma J Bowles; Judith A Burger; Guillaume B Stewart-Jones; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

10.  Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.

Authors:  José M Martinez-Navio; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.